Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma AB has announced an extra general meeting scheduled for October 13, 2025, to discuss significant changes in its corporate structure, including amendments to the articles of association and a reverse share split. These proposed changes are aimed at optimizing the company’s capital structure and enhancing its financial flexibility, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB operates in the biopharmaceutical industry, focusing on the development and commercialization of biosimilar drugs. The company aims to provide affordable and accessible treatments by leveraging its expertise in biosimilar development.
Average Trading Volume: 14,023,811
Technical Sentiment Signal: Sell
Current Market Cap: SEK685.4M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.